Therapeutic efficacy of artemether-lumefantrine for Plasmodium vivax infections in a prospective study in Guyana

Malaria Journal

Volumn 11, Issue , 2012, Pages

  Eibach, Daniel ^a,b   Ceron, Nicolas ^c   Krishnalall, Karanchand ^d   Carter, Keith ^e   Bonnot, Guillaume ^a   Bienvenu, Anne Lise ^a   Picot, Stéphane ^a  

^a UNIVERSITÉ LYON 1   (France)

^b EUROPEAN CENTRE FOR DISEASE PREVENTION AND CONTROL ECDC   (Sweden)

^c PAN AMERICAN HEALTH ORGANIZATION   (Guyana)

^d Ministry of Health Guyana   (Guyana)

^e PAN AMERICAN HEALTH ORGANIZATION   (United States)

Author keywords

Artemether lumefantrine; Chloroquine; Guyana; Malaria; Plasmodium vivax

Indexed keywords

ARTEMETHER PLUS BENFLUMETOL; CHLOROQUINE; PRIMAQUINE; PROTOZOAL DNA; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; ETHANOLAMINE DERIVATIVE; FLUORENE DERIVATIVE; MDR1 PROTEIN, PLASMODIUM VIVAX; MULTIDRUG RESISTANCE PROTEIN; PROTOZOAL PROTEIN;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; CHILD; CLINICAL EVALUATION; CODON; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GUYANA; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NONHUMAN; PLASMODIUM VIVAX; PLASMODIUM VIVAX MALARIA; PRESCHOOL CHILD; PROSPECTIVE STUDY; RECURRENT DISEASE; RELAPSE; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; CLINICAL TRIAL; DRUG COMBINATION; GENETICS; ISOLATION AND PURIFICATION; MIDDLE AGED; MISSENSE MUTATION; PARASITOLOGY; PATHOLOGY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTIMALARIALS; ARTEMISININS; CHILD; CHILD, PRESCHOOL; DNA, PROTOZOAN; DRUG COMBINATIONS; ETHANOLAMINES; FEMALE; FLUORENES; GUYANA; HUMANS; MALARIA, VIVAX; MALE; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; MUTATION, MISSENSE; PLASMODIUM VIVAX; PRIMAQUINE; PROSPECTIVE STUDIES; PROTOZOAN PROTEINS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84867625220     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-11-347     Document Type: Article

References (41)

1. World Health Organization, WHO Malaria Report World Health Organization 2011
2. Malaria in selected non-Amazonian countries of Latin America. Arevalo-Herrera M, Quĩones ML, Guerra C, Céspedes N, Giron S, Ahumada M, Pĩeros JG, Padilla N, Terrientes Z, Rosas A, Padilla JC, Escalante AA, Beier JC, Herrera S, Acta Trop 2011 121 303 314 21741349
3. Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective study. Nosten F, van Vugt M, Price R, Luxemburger C, Thway KL, Brockman A, McGready R, ter Kuile F, Looareesuwan S, White NJ, Lancet 2000 356 297 302 10.1016/S0140-6736(00)02505-8 11071185 (Pubitemid 30459588)
4. Effect of artemether-lumefantrine policy and improved vector control on malaria burden in KwaZulu-Natal. Barnes KI, Durrheim DN, Little F, Jackson A, Mehta U, Allen E, Dlamini SS, Tsoka J, Bredenkamp B, Mthembu DJ, White NJ, Sharp BL, South Africa. PLoS Med 2005 2 330
5. Impact of artemisinin-based combination therapy and insecticide-treated nets on malaria burden in Zanzibar. Bhattarai A, Ali AS, Kachur SP, Mårtensson A, Abbas AK, Khatib R, Al-Mafazy AW, Ramsan M, Rotllant G, Gerstenmaier JF, Molteni F, Abdulla S, Montgomery SM, Kaneko A, Björkman A, PLoS Med 2007 4 309 10.1371/journal.pmed.0040309 17988171 (Pubitemid 350220531)
6. Deployment of early diagnosis and mefloquine-artesunate treatment of falciparum malaria in Thailand: the Tak Malaria Initiative. Carrara VI, Sirilak S, Thonglairuam J, Rojanawatsirivet C, Proux S, Gilbos V, Brockman A, Ashley EA, McGready R, Krudsood S, Leemingsawat S, Looareesuwan S, Singhasivanon P, White N, Nosten F, PLoS Med 2006 3 183 10.1371/journal.pmed.0030183 16719547 (Pubitemid 43987828)
7. Effects of artemisinin derivatives on malaria transmissibility. Price RN, Nosten F, Luxemburger C, ter Kuile FO, Paiphun L, Chongsuphajaisiddhi T, White NJ, Lancet 1996 347 1654 1658 10.1016/S0140-6736(96)91488-9 8642959 (Pubitemid 26177386)
8. Evidence of artemisinin-resistant malaria in western Cambodia. Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM, N Engl J Med 2008 359 2619 2620 10.1056/NEJMc0805011 19064625
9. Artemisinin resistance in Plasmodium falciparum malaria. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, Lwin KM, Ariey F, Hanpithakpong W, Lee SJ, Ringwald P, Silamut K, Imwong M, Chotivanich K, Lim P, Herdman T, An SS, Yeung S, Singhasivanon P, Day NP, Lindegardh N, Socheat D, White NJ, N Engl J Med 2009 361 455 467 10.1056/NEJMoa0808859 19641202
10. Resistance of Plasmodium falciparum field isolates to in-vitro artemether and point mutations of the SERCA-type PfATPase6. Jambou R, Legrand E, Niang M, Khim N, Lim P, Volney B, Ekala MT, Bouchier C, Esterre P, Fandeur T, Mercereau-Puijalon O, Lancet 2005 366 1960 1963 10.1016/S0140-6736(05)67787-2 16325698 (Pubitemid 41713986)
11. Plasmodium vivax resistance to chloroquine? Rieckmann KH, Davis DR, Hutton DC, Lancet 1989 2 1183 1184 2572903 (Pubitemid 19275451)
12. Resistance to therapies for infection by Plasmodium vivax. Baird JK, Clin Microbiol Rev 2009 22 508 534 10.1128/CMR.00008-09 19597012
13. Plasmodium vivax resistance to chloroquine in Madagascar: clinical efficacy and polymorphisms in pvmdr1 and pvcrt-o genes. Barnadas C, Ratsimbasoa A, Tichit M, Bouchier C, Jahevitra M, Picot S, Ménard D, Antimicrob Agents Chemother 2008 52 4233 4240 10.1128/AAC.00578-08 18809933
14. Evaluation of chloroquine therapy for vivax and falciparum malaria in southern Sumatra, western Indonesia. Sutanto I, Endawati D, Ling LH, Laihad F, Setiabudy R, Baird JK, Malar J 2010 9 52 10.1186/1475-2875-9-52 20152016
15. Plasmodium vivax resistance to chloroquine in Dawei, southern Myanmar. Guthmann JP, Pittet A, Lesage A, Imwong M, Lindegardh N, Min Lwin M, Zaw T, Annerberg A, de Radiguès X, Nosten F, Trop Med Int Health 2008 13 91 98 10.1111/j.1365-3156.2007.01978.x 18291007 (Pubitemid 351271394)
16. The decreasing efficacy of chloroquine in the treatment of Plasmodium vivax malaria, in Sanliurfa, south-eastern Turkey. Kurcer MA, Simsek Z, Kurcer Z, Ann Trop Med Parasitol 2006 100 109 113 10.1179/136485906X86284 16492358 (Pubitemid 43325852)
17. Chloroquine resistant vivax malaria in a pregnant woman on the western border of Thailand. Rijken MJ, Boel ME, Russell B, Imwong M, Leimanis ML, Phyo AP, Muehlenbachs A, Lindegardh N, McGready R, Rénia L, Snounou G, Singhasivanon P, Nosten F, Malar J 2011 10 113 10.1186/1475-2875-10-113 21545737
18. Therapeutic responses of Plasmodium vivax and P. falciparum to chloroquine, in an area of western India where P. vivax predominates. Srivastava HC, Yadav RS, Joshi H, Valecha N, Mallick PK, Prajapati SK, Dash AP, Ann Trop Med Parasitol 2008 102 471 480 10.1179/136485908X311759 18782486
19. Failure of combined chloroquine and high-dose primaquine therapy for Plasmodium vivax malaria acquired in Guyana, South America. Phillips EJ, Keystone JS, Kain KC, Clin Infect Dis 1996 23 1171 1173 10.1093/clinids/23.5. 1171 8922821 (Pubitemid 126782788)
20. Chloroquine-resistant Plasmodium vivax, Brazilian Amazon. de Santana Filho FS, Arcanjo AR, Chehuan YM, Costa MR, Martinez-Espinosa FE, Vieira JL, Barbosa MG, Alecrim WD, Alecrim MG, Emerg Infect Dis 2007 13 1125 1126 10.3201/eid1307.061386 18214203 (Pubitemid 47048104)
21. Plasmodium vivax clinically resistant to chloroquine in Colombia. Soto J, Toledo J, Gutierrez P, Luzz M, Llinas N, Cedẽo N, Dunne M, Berman J, Am J Trop Med Hyg 2001 65 90 93 11508397 (Pubitemid 32744210)
22. Identification of the Plasmodium vivax mdr-like gene (pvmdr1) and analysis of single-nucleotide polymorphisms among isolates from different areas of endemicity. Brega S, Meslin B, de Monbrison F, Severini C, Gradoni L, Udomsangpetch R, Sutanto I, Peyron F, Picot S, J Infect Dis 2005 191 272 277 10.1086/426830 15609238 (Pubitemid 40096386)
23. World Health Organization, Methods for surveillance of antimalarial drug efficacy World Health Organization, Geneva 2009
24. World Health Organization, Monitoring Antimalarial Drug Resistance. WHO/CDC/CSR/EPH/2002.17 World Health Organization, Geneva 2002
25. Simultaneous identification of the four human Plasmodium species and quantification of Plasmodium DNA load in human blood by real-time polymerase chain reaction. de Monbrison F, Angei C, Staal A, Kaiser K, Picot S, Trans R Soc Trop Med Hyg 2003 97 387 390 10.1016/S0035-9203(03)90065-4 15259463 (Pubitemid 39186015)
26. Real-time PCR for dihydrofolate reductase gene single-nucleotide polymorphisms in Plasmodium vivax isolates. Brega S, de Monbrison F, Severini C, Udomsangpetch R, Sutanto I, Ruckert P, Peyron F, Picot S, Antimicrob Agents Chemother 2004 48 2581 2587 10.1128/AAC.48.7.2581-2587.2004 15215112 (Pubitemid 38823428)
27. Molecular markers of in vivo Plasmodium vivax resistance to amodiaquine plus sulfadoxine-pyrimethamine: mutations in pvdhfr and pvmdr1. Marfurt J, de Monbrison F, Brega S, Barbollat L, Müller I, Sie A, Goroti M, Reeder JC, Beck HP, Picot S, Genton B, J Infect Dis 2008 198 409 417 10.1086/589882 18582193
28. Confirmed vivax resistance to chloroquine and effectiveness of artemether-lumefantrine for the treatment of vivax malaria in Ethiopia. Yohannes AM, Teklehaimanot A, Bergqvist Y, Ringwald P, Am J Trop Med Hyg 2011 84 137 140 10.4269/ajtmh.2011.09-0723 21212216
29. Therapeutic responses to different antimalarial drugs in vivax malaria. Pukrittayakamee S, Chantra A, Simpson JA, Vanijanonta S, Clemens R, Looareesuwan S, White NJ, Antimicrob Agents Chemother 2000 44 1680 1685 10.1128/AAC.44.6. 1680-1685.2000 10817728 (Pubitemid 30340814)
30. Clinical efficacy of chloroquine versus artemether-lumefantrine for Plasmodium vivax treatment in Thailand. Krudsood S, Tangpukdee N, Muangnoicharoen S, Thanachartwet V, Luplertlop N, Srivilairit S, Wilairatana P, Kano S, Ringwald P, Looareesuwan S, Korean J Parasitol 2007 45 111 114 10.3347/kjp.2007.45.2.111 17570973
31. Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison. Ratcliff A, Siswantoro H, Kenangalem E, Maristela R, Wuwung RM, Laihad F, Ebsworth EP, Anstey NM, Tjitra E, Price RN, Lancet 2007 369 757 765 10.1016/S0140-6736(07)60160-3 17336652 (Pubitemid 46335820)
32. Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Li XQ, Björkman A, Andersson TB, Gustafsson LL, Masimirembwa CM, Eur J Clin Pharmacol 2003 59 429 442 10.1007/s00228-003-0636-9 12920490 (Pubitemid 37214951)
33. The use of artemether-lumefantrine for the treatment of uncomplicated Plasmodium vivax malaria. Bassat Q, PLoS Negl Trop Dis 2011 5 1325 10.1371/journal.pntd.0001325 22216359
34. Artemisinin combination therapy for vivax malaria. Douglas NM, Anstey NM, Angus BJ, Nosten F, Price RN, Lancet Infect Dis 2010 10 405 416 10.1016/S1473-3099(10)70079-7 20510281
35. Frequency of malaria relapse due to Plasmodium vivax in a non-endemic region (São Paulo, Brazil). Boulos M, Amato Neto V, Dutra AP, Di Santi SM, Shiroma M, Rev Inst Med Trop São Paulo 1991 33 143 146 10.1590/S0036-46651991000200009
36. Severe Plasmodium vivax malaria: a report on serial cases from Bikaner in northwestern India. Kochar DK, Das A, Kochar SK, Saxena V, Sirohi P, Garg S, Kochar A, Khatri MP, Gupta V, Am J Trop Med Hyg 2009 80 194 198 19190212
37. New developments in Plasmodium vivax malaria: severe disease and the rise of chloroquine resistance. Price RN, Douglas NM, Anstey NM, Curr Opin Infect Dis 2009 22 430 435 10.1097/QCO.0b013e32832f14c1 19571748
38. Pan American Health Organization, Guyana country cooperation strategy 2010-2015 Pan American Health Organization 2009 22358418
39. Identification of cryptic coinfection with Plasmodium falciparum in patients presenting with vivax malaria. Mayxay M, Pukritrayakamee S, Chotivanich K, Imwong M, Looareesuwan S, White NJ, Am J Trop Med Hyg 2001 65 588 592 11716119 (Pubitemid 33134597)
40. Dependence of malaria detection and species diagnosis by microscopy on parasite density. McKenzie FE, Sirichaisinthop J, Miller RS, Gasser RA Jr, Wongsrichanalai C, Am J Trop Med Hyg 2003 69 372 376 14640495 (Pubitemid 38248270)
41. Clinical trial of oral artesunate with or without high-dose primaquine for the treatment of vivax malaria in Thailand. Silachamroon U, Krudsood S, Treeprasertsuk S, Wilairatana P, Chalearmrult K, Mint HY, Maneekan P, White NJ, Gourdeuk VR, Brittenham GM, Looareesuwan S, Am J Trop Med Hyg 2003 69 14 18 12932090